Brief Communication | Published:

Attitudes toward genomic tumor profiling tests in Japan: patients, family members, and the public

Journal of Human Genetics (2019) | Download Citation

Abstract

Genomic tumor profiling tests (GTPTs) to find molecular targeted drugs for patients with advanced cancer are being introduced into clinical settings, which may result in secondary germline findings. Although small-scale qualitative studies have revealed patients’ attitudes toward GTPTs and preferences on receiving germline findings, no large-scale quantitative research exists that includes family members. We conducted anonymous surveys with 757 cancer patients (CPs), 763 family members (FMs), and 3697 general adults (GAs) in Japan. Awareness of GTPTs was low in all groups, however, both CPs and FMs showed a higher degree of recognition in the benefits of GTPTs. FMs wanted information on germline findings to be shared more than the CPs. Since advanced CPs may have psychological burdens that make it difficult to express their opinions on their therapeutic options and sharing germline findings, GTPTs should be offered with advanced care planning for patients.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. American Society of Clinical Oncology Policy Statement Update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33:3660–7.

  2. 2.

    Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.

  3. 3.

    Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, et al. Association of broad-based genomic sequencing with survival among patients with advanced non-small cell lung cancer in the community oncology setting. J Am Med Assoc. 2018;320:469–77.

  4. 4.

    Hilal T, Nakazawa M, Hodskins J, Villano JL, Mathew A, Goel G, et al. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. BMC Cancer. 2017;17:602.

  5. 5.

    Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19:249–55.

  6. 6.

    Johnson KJ, Gehlert S. Return of results from genomic sequencing: a policy discussion of secondary findings for cancer predisposition. J Cancer Policy. 2014;2:75–80.

  7. 7.

    May T. On the justifiability of ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. J Law Med Ethics. 2015;43:134–42.

  8. 8.

    Vears DF, Niemiec E, Howard HC, Borry P. How do consent forms for diagnostic high-throughput sequencing address unsolicited and secondary findings? A content analysis. Clin Genet. 2018;94:321–9.

  9. 9.

    Liang R, Meiser B, Smith S, Kasparian NA, Lewis CR, Chin M, et al. Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. Eur J Cancer Care. 2017;26:e12600.

  10. 10.

    Hamilton JG, Shuk E, Genoff MC, Rodriguez VM, Hay JL, Offit K, et al. Interest and attitudes of patients with advanced cancer with regard to secondary germline findings from tumor genomic profiling. J Oncol Pract. 2017;13:E590–601.

  11. 11.

    Bylstra Y, Lysaght T, Thrivikraman J, Watson S, Tan P. Ethical frameworks for obtaining informed consent in tumour profiling: an evidence-based case for Singapore. Hum Genom. 2017;11:31.

  12. 12.

    Gray SW, Hicks-Courant K, Lathan CS, Garraway L, Park ER, Weeks JC. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. JOP. 2012;8:329–35.

  13. 13.

    Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, et al. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer. 2016;122:1588–97.

Download references

Acknowledgements

We express our gratitude to all the survey participants. This research was supported by AMED under grant number JP18cm0106001, and JSPS KAKENHI Grant Number JP15H05913, JP18K09940.

Author information

Affiliations

  1. Department of Public Policy, The Institute of Medical Sciences, The University of Tokyo, Minato-ku, Tokyo, Japan

    • Akiko Nagai
    •  & Kaori Muto
  2. Graduate School of Interdisciplinary Information Studies, The University of Tokyo, Tokyo, Japan

    • Izen Ri
  3. Japan Society for the Promotion of Science, Tokyo, Japan

    • Izen Ri

Authors

  1. Search for Akiko Nagai in:

  2. Search for Izen Ri in:

  3. Search for Kaori Muto in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Kaori Muto.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s10038-018-0555-3